乐观
$245.24
情景价格
$217.260
-0.500 (-0.23%)收盘时
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.
Steris plc is a good buy right now due to its current price of $214.4, which is below analyst targets of $275 and $269, indicating significant upside potential. The company reported a strong Q1 2027 EPS of $2.59, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, showcasing solid market demand. However, the RSI is at 70.106, indicating it may be overbought, which is a risk to consider.
UBS
$275
2026-07-28
UBS
2026-07-28
目标价
$275
KeyBanc
$269
2026-05-13
KeyBanc
2026-05-13
目标价
$269
Morgan Stanley
—
2026-01-08
Morgan Stanley
2026-01-08
目标价
—
JPMorgan
—
2025-12-05
JPMorgan
2025-12-05
目标价
—
KeyBanc
$288
2025-07-22
KeyBanc
2025-07-22
目标价
$288
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

STERIS Acquires Xodus Medical for $2.1 Billion

STERIS plc Reports First Quarter Earnings Growth

Steris Reports Q1 2027 Earnings with Mixed Results

STERIS Reports Strong Q1 2027 Financial Results with Strategic Restructuring

STERIS Announces Quarterly Dividend Increase to $0.69
STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device manufacturing facilities, particularly those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).
Steris plc is a good buy right now due to its current price of $214.4, which is below analyst targets of $275 and $269, indicating significant upside potential. The company reported a strong Q1 2027 EPS of $2.59, exceeding expectations by $0.10, and a revenue growth of 7.9% year-over-year, showcasing solid market demand. However, the RSI is at 70.106, indicating it may be overbought, which is a risk to consider.
8 analysts cover STE: 6 rate it Buy, 2 Hold and 0 Sell.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。